What This Top Dividend Portfolio Is Holding Now: GlaxoSmithKline plc, HSBC Holdings plc And Vodafone Group plc

GlaxoSmithKline plc (LON:GSK), HSBC Holdings plc (LON:HSBA) and Vodafone Group plc (LON:VOD) are the heavyweight holdings of Temple Bar Investment Trust PLC (LON:TMPL).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Temple Bar Investment Trust (LSE: TMPL) is on track for 30 years of unbroken dividend growth after lifting its recent interim dividend by 3%. At a current share price of 1,191p, the trust is on a trailing yield of 3.1%.

Picking great dividend shares has helped Temple Bar outperform the FTSE All-Share Index over the past three, five and 10 years.

Let’s take a look at Temple Bar’s current top three holdings: GlaxoSmithKline (LSE: GSK), HSBC Holdings (LSE: HSBA) and Vodafone (LSE: VOD) (NASDAQ: VOD.US).

GlaxoSmithKline

Leading FTSE 100 pharma firm GlaxoSmithKline released satisfactory first-half results a couple of weeks ago. The drugs and consumer healthcare giant reaffirmed its full-year guidance of core earnings per share (EPS) growth of 3-4%, with turnover growth of around 1% (both at constant exchange rates).

The board declared a second-quarter dividend of 18p, the same as the first-quarter. The 36p payout to date represents a 5.9% increase on the same period last year. In the circumstances, the analyst consensus of 4% growth for the full year looks a little mean. However, the consensus for 2014 is for growth to accelerate to 6.8%.

At a recent share price of 1,671p, GlaxoSmithKline offers a dividend yield of 4.6% based on the 2013 forecasts, rising to 4.9% for 2014.

HSBC

Banking behemoth HSBC reported big growth numbers for profit and EPS within its half-year results announced earlier this week. However, the numbers weren’t quite as big as analysts were hoping for and the market was underwhelmed. The shares are currently down over 7% on their closing price last week.

The board announced a dividend of US$0.10 (up 11.1%) for the second quarter, delivering on a commitment made at the start of the year for that level of payout in each of the first three quarters. Analysts are expecting double-digit growth to be maintained for the full year, with more of the same for 2014.

At a recent share price of 704p, HSBC offers a dividend yield of 4.8% on 2013 forecasts, rising to 5.4% for 2014.

Vodafone

Telecoms titan Vodafone reported a mixed picture within its most recent trading update last month, but the chief executive told shareholders: “Although regulation, competitive pressures and weak economies, particularly in Southern Europe, continue to restrict revenue growth, we continue to lay strong foundations for the longer term”.

Vodafone’s share price continues to be buoyed by talk of a telephone-numbers-sized deal for its stake in US operator Verizon Wireless. If such a deal did happen it would obviously have potential implications for Vodafone’s dividend. The company would lose the ongoing cash flow from Verizon but would gain a whopping great pile of cash in one fell swoop.

In the meantime, Vodafone this year changed its dividend policy from at least 7% annual growth to the rather less appealing at least maintain the dividend at current levels. However, analysts are forecasting some growth in the payout this year and next — giving yields of 5.2% and 5.4%, respectively, at a recent share price of 199p.

Happy retirement!

If you already have GlaxoSmithKline, HSBC and Vodafone tucked away in your portfolio and are in the market for more blue-chip dividend dynamos, I recommend you help yourself to the very latest free Motley Fool report.

The Fool’s top analysts have identified five companies they believe will generate superior long-term growth in earnings and dividends. Such is their conviction about the quality of these businesses that they’ve called the report “5 Shares To Retire On“.

You can download this free report right now — simply click here.

> G A Chester does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline and Vodafone.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Mature black couple enjoying shopping together in UK high street
Investing Articles

What would £10k invested in the FTSE 250 last year be worth now?

Our writer evaluates the performance of the FTSE 250 in 2024 and considers the prospects of a value stock that…

Read more »

Investing Articles

Is Amazon still a top growth stock after its Q4 report?

With sales growth slowing and AI investments weighing on near-term profits, do investors have better stocks to consider buying than…

Read more »

Investing Articles

Down 15% and with a P/E below 9! Is the GSK share price still in deep value territory?

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing…

Read more »

Investing Articles

The Diageo share price is down 44% since 2021, but I won’t sell my shares!

The Diageo share price has almost halved since peaking in late 2021. But with the stock at a one-year low,…

Read more »

Man changing battery on electric bicycle
Investing Articles

Suddenly my FTSE income shares are giving me growth too – including this 9% yielder!

Harvey Jones loves his FTSE 100 dividend income shares but was disappointed by the lack of growth. Now it looks…

Read more »

Investing Articles

This FTSE AIM travel business could absolutely skyrocket in 2025

FTSE AIM stock Jet2 appears to be a bargain in plain sight. I’m desperately searching for reasons not to buy…

Read more »

Investing Articles

This Bank of England news makes me fear for Lloyds and its share price!

Warnings of weak economic growth, resurgent inflation, and falling interest rates pose a toxic cocktail for Lloyds' share price.

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

2 UK shares that could soar if interest rates sprint lower!

The Bank of England's latest meeting has fed speculation of swingeing interest rate cuts. I think these UK shares could…

Read more »